FDA Launches Safety Review of Mifepristone Abortion Pill

The Food and Drug Administration has initiated a safety review of mifepristone, the abortion medication used in medication abortions. The retrospective data analysis follows pressure from anti-abortion groups and could lead to new restrictions on the drug's use and distribution. The review's timing and scope remain unclear, but any resulting restrictions would affect Medicaid managed care organizations that cover reproductive health services. Medicaid is the largest payer for births in the United States and covers family planning services for millions of beneficiaries.

Maternal · Pharmacy · Managed Care